In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test. A panel of five proteins intended to guide treatment decisions in women with ovarian masses, the test was the culmination of — to summarize briefly — 10-plus years of research, two corporate name changes, and a Chapter 11 bankruptcy proceeding. As such, its release was greeted by Vermillion investors and observers as something of a watershed event.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.